{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T17:39:24Z","timestamp":1780076364739,"version":"3.54.0"},"reference-count":70,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Recent evidence suggests that Glucagon-Like Peptide-1 receptor agonists (GLP-1RAs) can assist in alcohol and related substance use disorders (ASUD). GLP-1RAs act on the same receptor targets as native GLP-1, but last from several hours to a week, compared to the 1.5\u20135 minutes for naturally occurring GLP-1. These receptor targets are the GLP-1 G-protein coupled receptors. They are part of a large family of 800\u20131000 receptors that are present throughout the human body, but higher in concentration in the hypothalamus, brainstem, and the gastrointestinal tract. Four hundred sixty of the G-protein coupled receptors are in the olfactory system, mediating smell and taste. Mechanistically, GLP-1RAs reduce activity in the dopamine reward system. The observational literature demonstrates that GLP-1RAs mitigate the risk of hospitalizations associated with alcohol use disorder and other substance use disorders. Semaglutide and liraglutide reduced ASUD-related hospitalizations compared to other GLP-1RAs and standard previously prescribed ASUD pharmacotherapy. This review will detail the evidence supporting this.<\/jats:p>","DOI":"10.1097\/crd.0000000000001145","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T05:00:29Z","timestamp":1765861229000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Glucagon-Like Peptide-1 Receptor Agonists: A Novel Indication for Substance Use Disorders?"],"prefix":"10.1097","author":[{"given":"Farage","family":"Ftiha","sequence":"first","affiliation":[{"name":"Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joey","family":"Ftiha","sequence":"additional","affiliation":[{"name":"Magen David Yeshiva High School, Brooklyn, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish A.","family":"Parikh","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY"},{"name":"Weill Department of Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Peterson","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY"},{"name":"Weill Department of Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"R1-20251216","doi-asserted-by":"crossref","first-page":"107312","DOI":"10.1016\/j.phrs.2024.107312","article-title":"IUPHAR review - glucagon-like peptide-1 (GLP-1) and substance use disorders: an emerging pharmacotherapeutic target.","volume":"207","author":"Bruns Vi","year":"2024","journal-title":"Pharmacol Res"},{"key":"R2-20251216","doi-asserted-by":"crossref","first-page":"1063033","DOI":"10.3389\/fphar.2023.1063033","article-title":"The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies.","volume":"14","author":"Jerlhag","year":"2023","journal-title":"Front Pharmacol"},{"key":"R3-20251216","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.3390\/ijms26115338","article-title":"GLP-1 analogues in the neurobiology of addiction: translational insights and therapeutic perspectives.","volume":"26","author":"Marquez-Meneses","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R4-20251216","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.physbeh.2019.03.029","article-title":"The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: a systematic review.","volume":"206","author":"Brunchmann","year":"2019","journal-title":"Physiol Behav"},{"key":"R5-20251216","doi-asserted-by":"crossref","first-page":"bqaf028","DOI":"10.1210\/endocr\/bqaf028","article-title":"GLP-1 receptor agonists: promising therapeutic targets for alcohol use disorder.","volume":"166","author":"Jerlhag","year":"2025","journal-title":"Endocrinology"},{"key":"R6-20251216","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/j.2040-4603.2020.tb00123.x","article-title":"Glucagon-like peptide-1: actions and influence on pancreatic hormone function.","volume":"10","author":"Davis","year":"2020","journal-title":"Compr Physiol"},{"key":"R7-20251216","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1.","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"key":"R8-20251216","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1001\/jama.2025.13665","article-title":"Current and future medications for obesity treatment.","volume":"334","author":"Kushner","year":"2025","journal-title":"JAMA"},{"key":"R9-20251216","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1476-5381.2011.01687.x","article-title":"The structure and function of the glucagon-like peptide-1 receptor and its ligands.","volume":"166","author":"Donnelly","year":"2012","journal-title":"Br J Pharmacol"},{"key":"R10-20251216","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"R11-20251216","first-page":"bqab216","article-title":"Expression profile of the GLP-1 receptor in the gastrointestinal tract and pancreas in adult female mice.","volume":"163","author":"Grunddal","year":"2022","journal-title":"Endocrinology"},{"key":"R12-20251216","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1210\/endo.137.7.8770921","article-title":"Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor.","volume":"137","author":"Bullock","year":"1996","journal-title":"Endocrinology"},{"key":"R13-20251216","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"R14-20251216","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1210\/jc.2019-00198","article-title":"Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline.","volume":"104","author":"LeRoith","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R15-20251216","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/dom.12593","article-title":"Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas.","volume":"18","author":"Smits","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"R16-20251216","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"key":"R17-20251216","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"R18-20251216","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"R19-20251216","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","article-title":"Glucagon-like peptide 1 in health and disease.","volume":"14","author":"Andersen","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"R20-20251216","doi-asserted-by":"crossref","first-page":"116776","DOI":"10.1016\/j.lfs.2019.116776","article-title":"Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity.","volume":"234","author":"Yaribeygi","year":"2019","journal-title":"Life Sci"},{"key":"R21-20251216","doi-asserted-by":"crossref","first-page":"112771","DOI":"10.1016\/j.physbeh.2019.112771","article-title":"Phasic dopamine responses to a food-predictive cue are suppressed by the glucagon-like peptide-1 receptor agonist exendin-4.","volume":"215","author":"Konanur","year":"2020","journal-title":"Physiol Behav"},{"key":"R22-20251216","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1523\/JNEUROSCI.6326-11.2012","article-title":"The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors.","volume":"32","author":"Dickson","year":"2012","journal-title":"J Neurosci"},{"key":"R23-20251216","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.2337\/db14-0849","article-title":"GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans.","volume":"63","author":"van Bloemendaal","year":"2014","journal-title":"Diabetes"},{"key":"R24-20251216","doi-asserted-by":"crossref","first-page":"114622","DOI":"10.1016\/j.physbeh.2024.114622","article-title":"Glucagon-like peptide 1 agonist and effects on reward behaviour: a systematic review.","volume":"283","author":"Badulescu","year":"2024","journal-title":"Physiol Behav"},{"key":"R25-20251216","doi-asserted-by":"crossref","first-page":"1439203","DOI":"10.3389\/fphar.2024.1439203","article-title":"The GLP-1 receptor agonist exendin-4 reduces taurine and glycine in nucleus accumbens of male rats, an effect tentatively involving the nucleus tractus solitarius.","volume":"15","author":"Edvardsson","year":"2024","journal-title":"Front Pharmacol"},{"key":"R26-20251216","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1038\/npp.2017.150","article-title":"Paraventricular thalamic control of food intake and reward: role of glucagon-like peptide-1 receptor signaling.","volume":"42","author":"Ong","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"R27-20251216","first-page":"1387432","article-title":"Can GLP-1 be a target for reward system related disorders? A qualitative synthesis and systematic review analysis of studies on palatable food, drugs of abuse, and alcohol.","volume":"14","author":"Eren-Yazicioglu","year":"2024","journal-title":"Front Behav Neurosci"},{"key":"R28-20251216","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/postgradmedj-2015-133249","article-title":"What is so special about smell? Olfaction as a model system in neurobiology.","volume":"92","author":"Barwich","year":"2016","journal-title":"Postgrad Med J"},{"key":"R29-20251216","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s00018-003-3273-7","article-title":"Olfactory receptors.","volume":"61","author":"Gaillard","year":"2004","journal-title":"Cell Mol Life Sci"},{"key":"R30-20251216","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0165-6147(99)01381-4","article-title":"Odorant receptors: a plethora of G-protein-coupled receptors.","volume":"20","author":"Dryer","year":"1999","journal-title":"Trends Pharmacol Sci"},{"key":"R31-20251216","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.tips.2024.01.004","article-title":"The structure and function of olfactory receptors.","volume":"45","author":"Wu","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"R32-20251216","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.tips.2022.08.003","article-title":"Odorant receptors as potential drug targets.","volume":"44","author":"Naressi","year":"2023","journal-title":"Trends Pharmacol Sci"},{"key":"R33-20251216","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/bs.mcb.2015.11.003","article-title":"Olfactory receptor signaling.","volume":"132","author":"Antunes","year":"2016","journal-title":"Methods Cell Biol"},{"key":"R34-20251216","doi-asserted-by":"crossref","first-page":"614884","DOI":"10.3389\/fnbeh.2020.614884","article-title":"Can GLP-1 be a target for reward system related disorders? A qualitative synthesis and systematic review analysis of studies on palatable food, drugs of abuse, and alcohol.","volume":"14","author":"Eren-Yazicioglu","year":"2020","journal-title":"Front Behav Neurosci"},{"key":"R35-20251216","doi-asserted-by":"crossref","first-page":"e69010","DOI":"10.1371\/journal.pone.0069010","article-title":"The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice.","volume":"8","author":"Egecioglu","year":"2013","journal-title":"PLoS One"},{"key":"R36-20251216","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders.","volume":"179","author":"Klausen","year":"2022","journal-title":"Br J Pharmacol"},{"key":"R37-20251216","doi-asserted-by":"crossref","first-page":"774050","DOI":"10.3389\/fnins.2021.774050","article-title":"An overview of appetite-regulatory peptides in addiction processes; from bench to bed side.","volume":"15","author":"Shevchouk","year":"2021","journal-title":"Front Neurosci"},{"key":"R38-20251216","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.3390\/nu12113564","article-title":"Meeting of minds around food addiction: insights from addiction medicine, nutrition, psychology, and neurosciences.","volume":"12","author":"Constant","year":"2020","journal-title":"Nutrients"},{"key":"R39-20251216","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1017\/S0029665119001162","article-title":"Food addiction, eating addiction and eating disorders.","volume":"79","author":"Hauck","year":"2020","journal-title":"Proc Nutr Soc"},{"key":"R40-20251216","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/ajcn\/nqaa343","article-title":"The concept of \u201cfood addiction\u201d helps inform the understanding of overeating and obesity: yes.","volume":"113","author":"Gearhardt","year":"2021","journal-title":"Am J Clin Nutr"},{"key":"R41-20251216","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev-nutr-110420-111710","article-title":"Is food addictive? A review of the science.","volume":"41","author":"Gearhardt","year":"2021","journal-title":"Annu Rev Nutr"},{"key":"R42-20251216","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jamapsychiatry.2014.1208","article-title":"Posttraumatic stress disorder symptoms and food addiction in women by timing and type of trauma exposure.","volume":"71","author":"Mason","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"R43-20251216","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.appet.2018.06.031","article-title":"Establishing a food addiction diagnosis using the Yale Food Addiction Scale: a closer look at the clinically significant distress\/functional impairment criterion.","volume":"129","author":"Ouellette","year":"2018","journal-title":"Appetite"},{"key":"R44-20251216","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/NMD.0000000000001555","article-title":"Food addiction: a comprehensive review.","volume":"210","author":"Florio","year":"2022","journal-title":"J Nerv Ment Dis"},{"key":"R45-20251216","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/bs.irn.2016.06.003","article-title":"Psychological and neurobiological correlates of food addiction.","volume":"129","author":"Kalon","year":"2016","journal-title":"Int Rev Neurobiol"},{"key":"R46-20251216","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3390\/nu10040477","article-title":"What is the evidence for \u201cfood addiction?\u201d A systematic review.","volume":"10","author":"Gordon","year":"2018","journal-title":"Nutrients"},{"key":"R47-20251216","doi-asserted-by":"crossref","first-page":"110937","DOI":"10.1016\/j.drugalcdep.2023.110937","article-title":"Does food use disorder exist? Item response theory analyses of a food use disorder adapted from the DSM-5 substance use disorder criteria in a treatment-seeking clinical sample.","volume":"251","author":"Chapron","year":"2023","journal-title":"Drug Alcohol Depend"},{"key":"R48-20251216","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamapsychiatry.2025.0679","article-title":"Glucagon-like peptide 1 receptor agonists and mental health.","volume":"82","author":"Pierret","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"R49-20251216","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1017\/S109285292400244X","article-title":"Are glucagon-like peptide-1 receptor agonists anti-consummatory drugs?","volume":"29","author":"Mansur","year":"2024","journal-title":"CNS Spectr"},{"key":"R50-20251216","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.3390\/ijms26083897","article-title":"On the pleiotropic actions of glucagon-like peptide-1 in its regulation of homeostatic and hedonic feeding.","volume":"26","author":"Sayers","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R51-20251216","doi-asserted-by":"crossref","first-page":"e230405","DOI":"10.1530\/JOE-23-0405","article-title":"The emerging role of glucagon-like peptide 1 in binge eating.","volume":"262","author":"Balantekin","year":"2024","journal-title":"J Endocrinol"},{"key":"R52-20251216","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing semaglutide and liraglutide for alcohol use disorder.","volume":"82","author":"L\u00e4hteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"R53-20251216","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1111\/dom.16453","article-title":"Glucagon-like peptide-1 receptor agonists and alcohol use disorders: an emerging unexpected beneficial effect.","volume":"27","author":"Scheen","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"R54-20251216","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial.","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"R55-20251216","doi-asserted-by":"crossref","first-page":"e2435247","DOI":"10.1001\/jamanetworkopen.2024.35247","article-title":"Semaglutide and opioid overdose risk in patients with type 2 diabetes and opioid use disorder.","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R56-20251216","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41386-019-0531-4","article-title":"Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats.","volume":"45","author":"Zhang","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"R57-20251216","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.brainresbull.2022.08.022","article-title":"Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats.","volume":"189","author":"Evans","year":"2022","journal-title":"Brain Res Bull"},{"key":"R58-20251216","doi-asserted-by":"crossref","first-page":"108599","DOI":"10.1016\/j.neuropharm.2021.108599","article-title":"A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats.","volume":"192","author":"Zhang","year":"2021","journal-title":"Neuropharmacology"},{"key":"R59-20251216","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainresbull.2022.08.023","article-title":"Acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, reduces cue- and drug-induced fentanyl seeking in rats.","volume":"189","author":"Urbanik","year":"2022","journal-title":"Brain Res Bull"},{"key":"R60-20251216","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/FBP.0000000000000609","article-title":"Glucagon-like peptide-1 receptor agonist, exendin-4, reduces reinstatement of heroin-seeking behavior in rats.","volume":"32","author":"Douton","year":"2021","journal-title":"Behav Pharmacol"},{"key":"R61-20251216","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/FBP.0000000000000685","article-title":"Acute glucagon-like peptide-1 receptor agonist liraglutide prevents cue-, stress-, and drug-induced heroin-seeking in rats.","volume":"33","author":"Douton","year":"2022","journal-title":"Behav Pharmacol"},{"key":"R62-20251216","doi-asserted-by":"crossref","first-page":"e13117","DOI":"10.1111\/adb.13117","article-title":"Glucagon-like peptide-1 receptor agonist, liraglutide, reduces heroin self-administration and drug-induced reinstatement of heroin-seeking behaviour in rats.","volume":"27","author":"Douton","year":"2022","journal-title":"Addict Biol"},{"key":"R63-20251216","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.neubiorev.2021.10.026","article-title":"A novel approach to treating opioid use disorders: dual agonists of glucagon-like peptide-1 receptors and neuropeptide Y receptors.","volume":"131","author":"Merkel","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"key":"R64-20251216","doi-asserted-by":"crossref","first-page":"114565","DOI":"10.1016\/j.physbeh.2024.114565","article-title":"Targeting GLP-1 receptors to reduce nicotine use disorder: preclinical and clinical evidence.","volume":"281","author":"Herman","year":"2024","journal-title":"Physiol Behav"},{"key":"R65-20251216","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s00213-023-06376-w","article-title":"Liraglutide attenuates nicotine self-administration as well as nicotine seeking and hyperphagia during withdrawal in male and female rats.","volume":"240","author":"Herman","year":"2023","journal-title":"Psychopharmacology (Berl)"},{"key":"R66-20251216","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nn.4540","article-title":"GLP-1 acts on habenular avoidance circuits to control nicotine intake.","volume":"20","author":"Tuesta","year":"2017","journal-title":"Nat Neurosci"},{"key":"R67-20251216","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/ntr\/ntab066","article-title":"Exenatide adjunct to nicotine patch facilitates smoking cessation and may reduce post-cessation weight gain: a pilot randomized controlled trial.","volume":"23","author":"Yammine","year":"2021","journal-title":"Nicotine Tob Res"},{"key":"R68-20251216","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/ntr\/ntaf005","article-title":"Exploring predictors of treatment response to GLP-1 receptor agonists for smoking cessation.","volume":"27","author":"Yammine","year":"2025","journal-title":"Nicotine Tob Res"},{"key":"R69-20251216","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s13063-023-07164-9","article-title":"Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP)\u2014a structured summary of a study protocol for a randomized controlled study.","volume":"24","author":"Lengsfeld","year":"2023","journal-title":"Trials"},{"key":"R70-20251216","doi-asserted-by":"crossref","first-page":"e072707","DOI":"10.1136\/bmjopen-2023-072707","article-title":"Exenatide as an adjunct to nicotine patch for smoking cessation and prevention of postcessation weight gain among treatment-seeking smokers with pre-diabetes and\/or overweight: study protocol for a randomised, placebo-controlled clinical trial.","volume":"13","author":"Yammine","year":"2023","journal-title":"BMJ Open"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T05:00:38Z","timestamp":1765861238000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":70,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001145","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]}}}